Dr. Rossetti on the Fast Track Designation of Momelotinib in Myelofibrosis
April 10th 2020James M. Rossetti, DO, discusses the FDA’s decision to grant momelotinib a fast track designation for use in patients with intermediate- or high-risk myelofibrosis who previously received a JAK inhibitor.
Read More